Acetazolamide in prevention of altitude disease
DOI:
https://doi.org/10.12775/PPS.2020.06.02.009Keywords
HAPE, HACE, AMS, acetazolamideAbstract
Mountain climbing is associated with many risky, life-threatening situations. One of the most common attacking diseases at altitudes above 2500 m is altitude disease (HAI). This disease consists of: acute alpine disease, cerebral oedema and pulmonary oedema at altitude. The best way to prevent altitude diseases is by means of alcomatisation and slow increase in altitude. Climbers should follow the principle "climb high, sleep low". Sometimes, however, time or inability to descend do not allow for acclimatization. In such conditions, it is necessary to use pharmaceuticals that prevent the occurrence of an illness of altitude. The following article discusses research on the most commonly used drug in the prevention of acute mountain disease - acetazolamide. This drug was first used in the 60s of the XX century, demonstrating its effectiveness in the prevention of mountain disease. Since then, it has been the subject of many studies.References
Barry PW., Pollard AJ.: Altitude illness, BMJ. 2003; 326(7395): 915-919.
Basnyat B., Gertsche JH., Johnson EW., Castro-Marin F., Inoue Y., Yeh Clement.: Efficacy of Low-Dose Acetazolamide (125 Mg BID) for the Prophylaxis of Acute Mountain Sickness: A Prospective, Double-Blind, Randomized, Placebo-Controlled Trial, High Alt Med Biol 2003; 4(1): 45-52.
Basnyat B., Hargove J., Holck PS., Srivastav S., Alekh K., Ghimire LV., Pandey K., Griffitsh A., Shankar R., Kaul K., Paudyal A., Stasiuk D., Basnyat R., Davis Ch., Southard A., Robinson C., Shandley T., Johnson DW., Zafren K., Williams S., Weiss EA., Farrar JJ., Swenson ER.: Acetazolamide fails to decrease pulmonary artery pressure at high altitude in partially acclimatized humans, High Alt Med Biol 2008; 9(3): 209-216.
Burns P., Lipman GS., Warner K., Jurkiewicz C., Phillips C., Sanders L., Soto M., Hackett P.: Altitude sickness prevention with ibuprofen relative to acetazolamide, Am J Med 2019; 132 (2): 247-251.
Carlsten Ch., Swenson ER., Stephen R.: A Dose-Response Study of Acetazolamide for Acute Mountain Sickness Prophylaxis in Vacationing Tourists at 12,000 Feet (3630 M), High Alt Med Biol 2004; 5(1): 33-39.
Dehnert C., Bärtsch P.: Acute Mountain Sickness and High-Altitude Cerebral Edema, Ther Umsch. 2017; 74(10): 535-541.
Derby R., deWeber K.: The athlete and high altitude, Curr Sports Med Rep 2010; 9(2): 79-85.
Dumont L, Mardirosoff C, Tramer MR.: Efficacy and harm of pharmacological prevention of acute mountain sickness: quantitative systemic review. BMJ. 2000;321:267–272.
Grissom CK., Roach RC., Sarnquist FH., Hackett PH.: Acetazolamide in the treatment of acute mountain sickness: clinical efficacy and effect on gas exchange, Ann Intern Med 1992; 116(6): 461-465.
Hartman-Ksycińska A., Kluz-Zawadzka J., Lewandowki B.: Choroba wysokościowa, Przegl Epidemiol 2016; 70(3): 490-499.
Joyce KE., Lucas SJE., Imray CHE., Balanos GM., Wright AD.: Advances in the Available Non-Biological Pharmacotherapy Prevention and Treatment of Acute Mountain Sickness and High Altitude Cerebral and Pulmonary Oedema, Expert Opin Pharmacother 2018; 19(17): 1891-1902.
Leshem E., Caine Y., Rosenber E., Maaravi Y., Hermesh H., Schwartz E.: Tadafil and Acetazolamide versus acetazolamide for the prevention of serve high-altitude illness, J Travel Med. 2012; 19(5): 308-10.
Lipman GS., Pomeranz D., Burns P., Phillips C., Cheffers M., Evans K., Jurkiewicz C., Juul N., Hackett P.: Budesonide versus acetazolamide for prevention of acute mountain sickness, Am J Med. 2018; 131: 200.e9-200.e16 .
Maggiorni M.: Mountaineering and altitude sickness, Ther Umsch 2001; 58(6): 387-393.
Mclntosh SE., Hemphill M., McDevitt M., Gurung T., Ghale M., Knott JR., Thapa GB., Basnyat B., Dow J., Weber D., Grissom CK.: Reduced acetazolamide dosing in countering altitude illness: a comparison of 62.5 vs 125 mg (the RADICAL trial), Wilderness Envirom Med 2019; 30(1): 12-21.
Piechocki J., Janus T.: Selected health-threatening and life-threatening conditions related to high altitude exposure, Anesthesiology Resuce Medicine Science Practice 2016; 10: 103-111.
Przybyłowski T., Zieliński J.: Problemy medyczne związane z przebywaniem na dużej wysokości, Pneumonol. Alergol. Pol 2004; 72: 134-138.
Ritchie ND., Baggott AV., Todd A.: Acetazolamide for the prevention of acute mountain sickness-a systematic review and meta-analysis, J Travel Med 2012; 19(5): 298-307.
Schmickl ChN., Owens RL., Orr JE., Edwards BA., Malhotra A.: Side effects of acetazolamide: a systematic review and meta-analysis assessing overall risk and dose dependence, BMJ Open Respir Res 2020; 7(1): e000557.
Swenson E.: Pharmacology of acute mountain sickness: old drugs and newer thinking, J Appl Physiol (1985) 2016; 120(2): 204-215.
Tissot van Patot M., Leadbetter H., Keyes LE., Maakeastad KM., Olson S., Hackett HP.: Prophylactic low-dose acetazolamid reduces the incidence and severity of acute mountain sickness, High Alt Med Biol. 2008; 9(4): 289-293.
Wright AD., Brearey SP., Imray Che.: High Hopes at High Altitudes: Pharmacotherapy for Acute Mountain Sickness and High-Altitude Cerebral and Pulmonary Oedema, Expert Opin Pharmacother 2008; 9(1): 119-127.
Zawadzki A.: Medycyna ratunkowa i katastrof. Warszawa PZWL 2006, 123–125.
Downloads
Published
How to Cite
Issue
Section
License
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 472
Number of citations: 0
